Research programme: kinase inhibitors - Exelixis
Alternative Names: EXEL 0862; EXEL 2280; EXEL 2819; EXEL 2942; EXEL 6309; EXEL-8232; mTORC1/mTORC2 inhibitor (XL388); XL 388Latest Information Update: 16 Jul 2016
At a glance
- Originator Exelixis
- Class Small molecules
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Aurora kinase A inhibitors; Insulin-like growth factor I inhibitors; Janus kinase 2 inhibitors; Mitogen-activated protein kinase kinase inhibitors; MTORC1 protein inhibitors; MTORC2 protein inhibitors; Phosphoric monoester hydrolase inhibitors; Phosphotransferase inhibitors; Proto-oncogene protein c-akt inhibitors; Proto-oncogene protein c-kit inhibitors; Raf kinase inhibitors; Src-family kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer; Myeloproliferative disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Myeloproliferative disorders in USA (PO)
- 19 Nov 2009 Pharmacodynamics data from preclinical trials in Cancer presented at the 21st AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2009) ,